A CASE OF INTERSTITIAL LUNG DISEASE TURNED OUT TO BE SYSTEMIC SCLEROSIS
Abstract
Abstract :
Although most common cause of ILD is idiopathic, It is estimated that approximately 15 of patients with ILD have an underlying connective tissue disorder. CTDs may be subtle, it is often difficult for clinicians to identify an underlying CTD in individuals who first or sole recognized as a case of ILD. Clinically significant ILD develops in 16-43 percent of patients with Systemic sclerosis. Over the period of time with the availability of angiotensin converting enzyme inhibitors frequency of scleroderma renal crisis associated deaths have significantly declined, while pulmonary complications (interstitial lung disease and pulmonary artery hypertension) still account for 25 of all cause of death in this group of atients. If left untreated outlook for patients with scleroderma related lung disease is worse warranting a speedy diagnosis . Here is a case report of young reproductive woman who presented with exertional dyspnoea diagnosed as interstitial lung disease, while on treatment she presented with florid skin manifestation diagnosed as scleroderma.
Keyword :Scleroderma, Pulmonary hypertension, Connective tissue disorder, Systemic sclerosis
Full Text:
PDFReferences
Harrison principles of internal medicine
Kelly,s textbook of rheumatology
. White, B Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003; 29,
Jacobsen, S, Ullman, S, Shen, GQ, et al Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemicsclerosis. J Rheumatol 2001
burt , autologous transplantation vs pulse cyclophosphamide therapy 2010; 45;234
Bargagli E, Galeazzi M, Bellisai F, et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008; 75:346.
. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49:271.
Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 2005; 17:737.
Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39:269.
Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University